AI-Designed Antibody HXN-1001 Enters Phase 2 Clinical

Title

AI-Designed Antibody HXN-1001 Enters Phase 2 Clinical

Content

Earendil Labs has secured $787 million in Series B financing to advance its pipeline of AI-designed antibodies, with the lead asset HXN-1001 — a half-life-extended anti-TL1A antibody — entering a Phase IIa trial in patients with ulcerative colitis. The financing round was led by a top-tier syndicate including OrbiMed, RA Capital Management, and Two Sigma Ventures, signaling strong investor confidence in AI-driven drug discovery. HXN-1001 was designed using Earendil Labs proprietary AI platform, which leverages machine learning to optimize antibody sequences, developability, and pharmacological properties in silico before experimental validation. Earendil Labs CEO stated that the funding will accelerate clinical development, expand the AI discovery pipeline, and support IND-enabling studies for additional assets targeting inflammatory bowel disease and other immune-mediated conditions. The companys AI platform generates and evaluates millions of antibody variants computationally, dramatically reducing the time and cost of traditional antibody engineering. Earendil Labs is among a new wave of biotech startups using generative AI to design therapeutic antibodies de novo, bypassing conventional hybridoma or phage display methods. With the global antibody drugs market valued at over $200 billion, AI-designed antibodies like HXN-1001 represent a significant convergence of artificial intelligence and biopharmaceutical development.

URL